How developers can engage with EMA
Antimicrobial resistance (AMR) is a growing silent pandemic that demands immediate and decisive action.
In Europe, at least 35,000 people die from antibiotic-resistant infections every year, with 1 in 5 bacterial infections already resistant to antibiotics. Without immediate action, annual deaths could rise to 390,000 by 2050.
Academia and pharma industry, big and small, must prioritise innovation, research & development of novel antimicrobials, alternatives to antimicrobials and quick diagnostics…
